Close Menu

NEW YORK — Atomo Diagnostics said on Thursday that it has signed an agreement to initially provide nearly 400,000 of its blood testing devices, and potentially millions more over the rest of the year, to NG Biotech for use for its recently launched SARS-CoV-2 test.

Atomo also said that it has closed an oversubscribed A$30 million ($18.2 million) initial public offering at A$.20 per share. The company expects to float its shares on the Australian Securities Exchange in mid-April.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.